S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

VXRT Vaxart Inc

0.703675

-0.04533 (-6.05%)

Last Updated: 03:49:22

Delayed by 15 minutes

Unknown (sec Staff)

This regulatory filing also includes additional resources:
filename1.pdf

Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Vaxart Charts.

Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Vaxart Charts.

Vaxart, Inc. News

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Tuesday 30 April 2024 (3 days ago) • GlobeNewswire Inc.

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Wednesday 27 March 2024 (1 month ago) • GlobeNewswire Inc.

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 20 March 2024 (1 month ago) • GlobeNewswire Inc.

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.

U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb
Thursday 14 March 2024 (2 months ago) • IH Market News

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Friday 8 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 16 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Tuesday 6 February 2024 (3 months ago) • GlobeNewswire Inc.

More Vaxart, Inc. News Articles

Australia And New Zealan...

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions